321 related articles for article (PubMed ID: 18795925)
21. Effect of tyrosine kinase inhibitor STI571 on the kinase activity of wild-type and various mutated c-kit receptors found in mast cell neoplasms.
Zermati Y; De Sepulveda P; Féger F; Létard S; Kersual J; Castéran N; Gorochov G; Dy M; Ribadeau Dumas A; Dorgham K; Parizot C; Bieche Y; Vidaud M; Lortholary O; Arock M; Hermine O; Dubreuil P
Oncogene; 2003 Feb; 22(5):660-4. PubMed ID: 12569358
[TBL] [Abstract][Full Text] [Related]
22. Specific c-kit mutations in sinonasal natural killer/T-cell lymphoma in China and Japan.
Hongyo T; Li T; Syaifudin M; Baskar R; Ikeda H; Kanakura Y; Aozasa K; Nomura T
Cancer Res; 2000 May; 60(9):2345-7. PubMed ID: 10811105
[TBL] [Abstract][Full Text] [Related]
23. Altered metabolism of mast-cell growth factor (c-kit ligand) in cutaneous mastocytosis.
Longley BJ; Morganroth GS; Tyrrell L; Ding TG; Anderson DM; Williams DE; Halaban R
N Engl J Med; 1993 May; 328(18):1302-7. PubMed ID: 7682288
[TBL] [Abstract][Full Text] [Related]
24. Identification of the M541L sequence variation of the transmembrane KIT domain in Merkel cell carcinoma.
Krasagakis K; Metaxari M; Zervou M; Stathopoulos EN; Eberle J; Kanitakis J; Georgoulias V; Krüger-Krasagakis S; Tavernarakis N; Tosca AD
Anticancer Res; 2011 Mar; 31(3):807-11. PubMed ID: 21498700
[TBL] [Abstract][Full Text] [Related]
25. Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis.
Longley BJ; Metcalfe DD; Tharp M; Wang X; Tyrrell L; Lu SZ; Heitjan D; Ma Y
Proc Natl Acad Sci U S A; 1999 Feb; 96(4):1609-14. PubMed ID: 9990072
[TBL] [Abstract][Full Text] [Related]
26. Pathogenesis, clinical features, and treatment advances in mastocytosis.
Pardanani A; Akin C; Valent P
Best Pract Res Clin Haematol; 2006; 19(3):595-615. PubMed ID: 16781490
[TBL] [Abstract][Full Text] [Related]
27. The c-Kit/D816V mutation eliminates the differences in signal transduction and biological responses between two isoforms of c-Kit.
Pedersen M; Rönnstrand L; Sun J
Cell Signal; 2009 Mar; 21(3):413-8. PubMed ID: 19049823
[TBL] [Abstract][Full Text] [Related]
28. T670X KIT mutations in gastrointestinal stromal tumors: making sense of missense.
Negri T; Pavan GM; Virdis E; Greco A; Fermeglia M; Sandri M; Pricl S; Pierotti MA; Pilotti S; Tamborini E
J Natl Cancer Inst; 2009 Feb; 101(3):194-204. PubMed ID: 19176456
[TBL] [Abstract][Full Text] [Related]
29. The biology of Kit in disease and the application of pharmacogenetics.
Akin C; Metcalfe DD
J Allergy Clin Immunol; 2004 Jul; 114(1):13-9; quiz 20. PubMed ID: 15241338
[TBL] [Abstract][Full Text] [Related]
30. C-kit inhibition by imatinib mesylate attenuates progenitor cell expansion and inhibits liver tumor formation in mice.
Knight B; Tirnitz-Parker JE; Olynyk JK
Gastroenterology; 2008 Sep; 135(3):969-79, 979.e1. PubMed ID: 18602920
[TBL] [Abstract][Full Text] [Related]
31. Novel, activating KIT-N822I mutation in familial cutaneous mastocytosis.
Wasag B; Niedoszytko M; Piskorz A; Lange M; Renke J; Jassem E; Biernat W; Debiec-Rychter M; Limon J
Exp Hematol; 2011 Aug; 39(8):859-65.e2. PubMed ID: 21689725
[TBL] [Abstract][Full Text] [Related]
32. Imatinib targeting of KIT-mutant oncoprotein in melanoma.
Jiang X; Zhou J; Yuen NK; Corless CL; Heinrich MC; Fletcher JA; Demetri GD; Widlund HR; Fisher DE; Hodi FS
Clin Cancer Res; 2008 Dec; 14(23):7726-32. PubMed ID: 19047099
[TBL] [Abstract][Full Text] [Related]
33. Identification of c-kit mutations-independent neoplastic cell proliferation of canine mast cells.
Ohmori K; Kawarai S; Yasuda N; Tanaka A; Matsuda H; Nishimura R; Sasaki N; Tsujimoto H; Masuda K
Vet Immunol Immunopathol; 2008 Nov; 126(1-2):43-53. PubMed ID: 18687474
[TBL] [Abstract][Full Text] [Related]
34. Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit.
Akin C; Brockow K; D'Ambrosio C; Kirshenbaum AS; Ma Y; Longley BJ; Metcalfe DD
Exp Hematol; 2003 Aug; 31(8):686-92. PubMed ID: 12901973
[TBL] [Abstract][Full Text] [Related]
35. Target-driven exploratory study of imatinib mesylate in children with solid malignancies by the Innovative Therapies for Children with Cancer (ITCC) European Consortium.
Geoerger B; Morland B; Ndiaye A; Doz F; Kalifa G; Geoffray A; Pichon F; Frappaz D; Chatelut E; Opolon P; Hain S; Boderet F; Bosq J; Emile JF; Le Deley MC; Capdeville R; Vassal G;
Eur J Cancer; 2009 Sep; 45(13):2342-51. PubMed ID: 19362466
[TBL] [Abstract][Full Text] [Related]
36. Overexpression of the KIT/SCF in uveal melanoma does not translate into clinical efficacy of imatinib mesylate.
Hofmann UB; Kauczok-Vetter CS; Houben R; Becker JC
Clin Cancer Res; 2009 Jan; 15(1):324-9. PubMed ID: 19118061
[TBL] [Abstract][Full Text] [Related]
37. Baseline and stimulated turnover of cell surface c-Kit expression in different types of human mast cells.
Babina M; Rex C; Guhl S; Thienemann F; Artuc M; Henz BM; Zuberbier T
Exp Dermatol; 2006 Jul; 15(7):530-7. PubMed ID: 16761962
[TBL] [Abstract][Full Text] [Related]
38. C-kit Asp-816-Val mutation analysis in patients with mastocytosis.
Verzijl A; Heide R; Oranje AP; van Schaik RH
Dermatology; 2007; 214(1):15-20. PubMed ID: 17191042
[TBL] [Abstract][Full Text] [Related]
39. Molecular basis of the constitutive activity and STI571 resistance of Asp816Val mutant KIT receptor tyrosine kinase.
Foster R; Griffith R; Ferrao P; Ashman L
J Mol Graph Model; 2004 Oct; 23(2):139-52. PubMed ID: 15363456
[TBL] [Abstract][Full Text] [Related]
40. "Occult" mastocytosis with activating c-kit point mutation evolving into systemic mastocytosis associated with plasma cell myeloma and secondary amyloidosis.
Sotlar K; Saeger W; Stellmacher F; Stahmer J; Jäckle S; Valent P; Horny HP
J Clin Pathol; 2006 Aug; 59(8):875-8. PubMed ID: 16873565
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
